"Cytogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.
| Descriptor ID |
D003582
|
| MeSH Number(s) |
H01.158.273.343.180
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytogenetics".
Below are MeSH descriptors whose meaning is more specific than "Cytogenetics".
This graph shows the total number of publications written about "Cytogenetics" by people in this website by year, and whether "Cytogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 8 | 8 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytogenetics" by people in Profiles.
-
SETD2 safeguards the genome against isochromosome formation. Proc Natl Acad Sci U S A. 2023 09 26; 120(39):e2303752120.
-
Status and Prospects of Fluorescence In Situ Hybridization Automation-A Survey among Laboratory Directors and Their Designates. Genes (Basel). 2022 11 11; 13(11).
-
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021 11 11; 138(19):1885-1895.
-
Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. Leuk Res. 2021 09; 108:106616.
-
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020 05 04; 10(5):48.
-
t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. J Mol Diagn. 2019 03; 21(2):343-351.
-
Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement. J Natl Compr Canc Netw. 2016 06; 14(6):708-11.
-
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; 127(24):2955-62.
-
ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014 Oct; 28(10):2090-2.
-
Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1139-44.